



AMURA

Press Release

Amura announces positive results for its osteoporosis programme

Cambridge, U.K. – 18th September 2007

Amura Holdings Limited ("Amura") today announced that lead compounds for their osteoporosis programme have demonstrated efficacy in a non-human primate study. The acute study, designed to monitor the pharmacokinetic and pharmacodynamic (PK/PD) effects of Amura's cathepsin K inhibitors, demonstrated that oral administration of compounds resulted in the sustained and potent reduction of serum bone turnover biomarkers- which clinically correlates with a significant reduction in fracture rates. The compounds were well tolerated and showed no adverse effects. The results further support progression of these compounds towards the clinic, offering the potential for new osteoporosis treatments.

Cathepsin K, which is a member of a large family (CAC1) of cysteine peptidases, is an enzyme which breaks down the collagen bone matrix as part of a normal biological process. In disease conditions such as osteoporosis, the relative cathepsin K activity is increased, thereby increasing bone degradation. Drugs that inhibit cathepsin K could provide a novel method for the treatment of osteoporosis and/or bone metastasis.

Amura's compounds are derived from the proprietary AMcore™ scaffold, which provides a turnkey solution for inhibitor design against cysteine peptidases of the CAC1 family. Cysteine peptidases are involved in several diseases and the AMcore™ scaffold provides a powerful platform for discovery of drugs with potential utility against a range of commercially attractive therapeutic targets. The company has further programmes selectively targeting cathepsin S and other members of this family.

Amura intends to out-license its cathepsin K inhibitor products for clinical development.

Additional information about Amura is available at the company website: <http://www.amura.co.uk/>

Contact:

Dr Dan Roach
Avlar BioVentures Limited

☎ +44 (0)1954 211515
☎ +44 (0)1954 211516
✉ DRoach@avlar.com